JP Morgan Downgrades Enact Holdings to Underweight, Lowers Price Target to $44
JP Morgan analyst Richard Shane downgrades Enact Holdings (NASDAQ:ACT) from Neutral to Underweight and lowers the price target from $48 to $44.
Stocks · News reference
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Standard Motor Products, Phoenix Education Partners And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures were mixed. Standard Motor Products fell 3.2% after naming an interim CFO, while several other stocks declined in premarket trading.
Enact Holdings Q2 2026 Earnings Call Transcript
Enact Holdings (NASDAQ:ACT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
Wolfe Research Downgrades Insmed to Peer Perform
Wolfe Research analyst Andy Chen downgrades Insmed (NASDAQ:INSM) from Outperform to Peer Perform.
HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.